Mannkind, Game-Chancer in Sachen Diabetik? (Seite 184)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 01.06.24 01:01:10 von
neuester Beitrag 01.06.24 01:01:10 von
Beiträge: 6.843
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 10
Gesamt: 594.762
Gesamt: 594.762
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: NNFN
4,3150
EUR
+0,16 %
+0,0070 EUR
Letzter Kurs 10:30:35 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
08.03.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2202 | +309,05 | |
| 3,2000 | +52,38 | |
| 6,8100 | +48,69 | |
| 0,9700 | +40,99 | |
| 1,0000 | +24,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8100 | -24,27 | |
| 2,2825 | -41,17 | |
| 0,9500 | -43,11 | |
| 1,0474 | -46,29 | |
| 2,0400 | -58,87 |
Beitrag zu dieser Diskussion schreiben
Feedback
..über 2 Euro darf hier geklingelt werden..
Hab ich auch gerade gelesen auf nasdaq.com :-)
Super Meldung, der 105 Millionen Vertrag mit United Therapeutics tritt ab sofort in Kraft:
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
GlobeNewswire•October 16, 2018
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The requisite waiting period expired on October 15, 2018, and the agreement became effective the same day.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. [uthr‑g]
Damit sind die Bankrottfantasien endlich vom Tisch, Afrezza wächst und die Pipeline auch!
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
GlobeNewswire•October 16, 2018
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The requisite waiting period expired on October 15, 2018, and the agreement became effective the same day.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. [uthr‑g]
Damit sind die Bankrottfantasien endlich vom Tisch, Afrezza wächst und die Pipeline auch!
Sehe das so.
Je mehr Trx,desto mehr Shorts,
Wo ist die Logik dahinter.
Den Kurs Anstieg verhindern? Mnkd von frischen Mitteln abbringen.
Diabetikern Schaden
..
Demnach wäre die Logik pervers.und,wer schortet die Aktie,lässt sich das ermitteln online?
Das sind doch kein kleinanleger.imo
Wer hat ideen
Je mehr Trx,desto mehr Shorts,
Wo ist die Logik dahinter.
Den Kurs Anstieg verhindern? Mnkd von frischen Mitteln abbringen.
Diabetikern Schaden
..
Demnach wäre die Logik pervers.und,wer schortet die Aktie,lässt sich das ermitteln online?
Das sind doch kein kleinanleger.imo
Wer hat ideen
Also liebe Freunde, wie weit werden die Shors noch gehen, auf 50, 60 oder 70 Millionen Aktien? Ich weiß es nicht. Aber offensichtlich ist, dass die verkaufen was das Zeug hält. Hier wird dagegen gehalten, ich bin sprachlos.
Wenn das mal nicht in die Hose geht. Hoffentlich!!!!!!!!!!!!!!!
Wenn das mal nicht in die Hose geht. Hoffentlich!!!!!!!!!!!!!!!
Trading Spotlight
Interessanter Jahresvergleich, fast Verdreifachung der revenues, das wird:
EatSleepBreatheMNKD
Oct 12th, 4:11 pm
$MNKD
10/5/18 $906.15K
10/6/17 $351.55K
Increase $554.60K
% increase 157.8%
15
EatSleepBreatheMNKD
Oct 12th, 4:11 pm
$MNKD
10/5/18 $906.15K
10/6/17 $351.55K
Increase $554.60K
% increase 157.8%
15
Männer ich hoffe auf den erfolg shorts scheint es noch nicht zu jucken
Fast 1 Millionen US Dollar bei 643 Rezepten, der CEO sprach von 5.000 pro Woche in 1-2 Jahren!
Dazu die Technosphere Technologie, perfekter short squeeeezzzzzeeee in den nächsten 3-6 Monaten!
Dazu die Technosphere Technologie, perfekter short squeeeezzzzzeeee in den nächsten 3-6 Monaten!
Antwort auf Beitrag Nr.: 58.943.331 von price-of-success am 12.10.18 14:57:18Danke für die Info LUBI!
Naja, trotzdem nicht schlecht. Mühselig ernährt sich das Eichhörnchen.
Es wird schön langsam. Warten wir auf Brasilien, Indien, Mexico, Australien, Europa etc. etc. und schon haben wir, sagen ma mal, 3-4 tsd.
Naja, trotzdem nicht schlecht. Mühselig ernährt sich das Eichhörnchen.
Es wird schön langsam. Warten wir auf Brasilien, Indien, Mexico, Australien, Europa etc. etc. und schon haben wir, sagen ma mal, 3-4 tsd.
um 7 verschätzt
heute all time high- aber nur 643
patten1962
Oct 12th, 2:29 pm
$MNKD
Week ending 10/5/18
TRx 643 vs 585
NRx 341 vs 296
TRx $906.15k vs $797.35k
NRx $480.76k vs $381.62k
dyor
bei TRX fällt in Bälde in 1 Mio pro Woche. IMO
source: stoktwits.com
heute all time high- aber nur 643
patten1962
Oct 12th, 2:29 pm
$MNKD
Week ending 10/5/18
TRx 643 vs 585
NRx 341 vs 296
TRx $906.15k vs $797.35k
NRx $480.76k vs $381.62k
dyor
bei TRX fällt in Bälde in 1 Mio pro Woche. IMO
source: stoktwits.com
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
